



6-7 March
2024

Congress Center
Basel | Switzerland



8th AMR Conference

Novel Antimicrobials & AMR Diagnostics

amr-conference.com
#AMRconference

Organization: bamconn GmbH | Erholungsweg 51 | 13509 Berlin
Boris Mannhardt | info@bamconn.eu | Tel. +49 (0)176 101 439 86

bamconn



SSID: Free-Messe-Basel
Free SMS Login (one login for each device)

About the AMR Conference

The #AMRconference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss **strategies and specific challenges faced by the innovation ecosystem** in bringing new antimicrobial treatments and diagnostics to the market.

The conference is the one-stop shop to catch up with the latest trends in the development of AMR products, by covering **scientific, regulatory, financial and policy topics**. Besides high-level talks, the conference is a great place to network and exchange views on innovative technologies, development paths and alternative business models with your peers. The conference also offers a **one-to-one partnering** to facilitate interactions.

Once more, the 8th edition will cover the whole innovation value chain, including scientific breakthrough, preclinical and clinical development, but also financial topics such as public funding for R&D, market incentive and investors' perspective. Specific sessions will also be dedicated to **phage therapy, diagnostics, antifungals and anti-tuberculosis drug combinations**. There will also be a special focus on **One Health** and on how **artificial intelligence** can foster prevention and smart use of antibiotics. Among other highlights are a **start-up pitch**, hosted by the pharma-backed incubator INCATE, and a **presentation of scientific posters**.

The AMR Conference is jointly organized by BEAM Alliance and bamconn GmbH. It was started in 2017 as part of the annual "Berlin Conference on Life Sciences" series which was established twelve years ago as an event format to discuss the challenges of SME-driven innovation for the health market and to offer a **platform for meeting experts from business, science, clinics, finance, regulatory affairs and intellectual property**.

The BEAM Alliance is one of the major supporting partners of the AMR Conference. Launched in June 2015, the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance gathers more than 70 small and medium-sized European biotech and diagnostics companies committed to developing innovative products for fending off antibiotic-resistant pathogens. BEAM Alliance carries the voice of SMEs to support policies and incentives in antimicrobial research and development in Europe.

bamconn GmbH was established in November 2022 as a spin-off of BIOCOM AG and continues its entire event management as an independent company. It is built on more than 15 years of experience in the planning, organization and implementation of scientific events and exhibitions. The portfolio covers the entire spectrum from small workshops with 20 participants to multi-day international conferences for up to 2,000 people as well as exhibitions on the topic of bioeconomy throughout Europe. Customers for whom the bamconn team worked so far are companies, research institutions, associations and federal ministries as well as subordinate authorities and EU-funded projects.

At a glance

Conference Day 1 • 6 March 2024

09:00 - 11:00	BEAM Alliance General Assembly (BEAM members only) Room Kairo page 6		
	Pre-conference workshop		
09:30 - 11:00	“Milestone-driven R&D – opportunities and challenges” Room Shanghai page 6		
10:00 - 19:00	1-to-1 Partnering Meetings		
10:00 - 19:30	Poster presentations and exhibition open		
11:30 - 13:00	Opening Session 2024, a decisive year – update on the AMR environment Room Shanghai page 6		
13:00 - 13:15	Announcement of new CARB-X funding rounds Room Shanghai page 6		
13:15 - 14:00	Lunch break poster presentation & exhibition		
14:00 - 15:30	Parallel Sessions		
	Taking actions on pull incentives Room Shanghai page 7	Preclinical models to optimize translation to human Room Delhi page 7	Vaccines to keep AMR at bay Room Kairo page 7
15:30 - 16:00	Networking break poster session & exhibition		
16:00 - 17:30	Parallel Sessions		
	Meaningful clinical trials: combining regulatory and clinical differentiation needs Room Shanghai page 8	Novel disruptive approaches to fight AMR Room Delhi page 8	How can AI foster prevention and smart use of antibiotics in a One Health world? Room Kairo page 8
17:30 - 18:00	Networking break poster session & exhibition		
18:00 - 19:30	Start-up pitch Room Shanghai page 9		
19:30 - 21:30	Reception in the exhibition hall		

Day 1
6 Mar.

Conference Day 2 • 7 March 2024

08:00 - 18:30	Registration, poster presentations and exhibition open					
08:30 - 18:00	1-to-1 Partnering Meetings					
08:30 - 09:30	Plenary Session A phage cocktail for breakfast? Room Shanghai page 10					
09:30 - 10:00	Networking break poster presentation & exhibition					
10:00 - 11:30	Parallel Sessions <table><tr><td>Making the case for investing in AMR R&D Room Shanghai page 10</td><td>Tuberculosis: new tools against an old enemy Room Delhi page 10</td><td>New tricks to combat fungal infections Room Kairo page 10</td></tr></table>			Making the case for investing in AMR R&D Room Shanghai page 10	Tuberculosis: new tools against an old enemy Room Delhi page 10	New tricks to combat fungal infections Room Kairo page 10
Making the case for investing in AMR R&D Room Shanghai page 10	Tuberculosis: new tools against an old enemy Room Delhi page 10	New tricks to combat fungal infections Room Kairo page 10				
11:30 - 13:00	Lunch break poster presentation & exhibition					
13:00 - 14:30	Parallel Sessions <table><tr><td>Push funding: a lifeline for R&D Room Shanghai page 11</td><td>Fast, reliable and cost-effective diagnostics Room Delhi page 11</td><td>The true value of anti-microbial products Room Kairo page 11</td></tr></table>			Push funding: a lifeline for R&D Room Shanghai page 11	Fast, reliable and cost-effective diagnostics Room Delhi page 11	The true value of anti-microbial products Room Kairo page 11
Push funding: a lifeline for R&D Room Shanghai page 11	Fast, reliable and cost-effective diagnostics Room Delhi page 11	The true value of anti-microbial products Room Kairo page 11				
14:30 - 15:00	Networking break poster presentation & exhibition					
15:00 - 16:30	Parallel Sessions <table><tr><td>Greatest reach to the greatest need Room Shanghai page 12</td><td>Leveraging the power of diagnostics in clinical practice Room Delhi page 12</td><td>Technology update Room Kairo page 12</td></tr></table>			Greatest reach to the greatest need Room Shanghai page 12	Leveraging the power of diagnostics in clinical practice Room Delhi page 12	Technology update Room Kairo page 12
Greatest reach to the greatest need Room Shanghai page 12	Leveraging the power of diagnostics in clinical practice Room Delhi page 12	Technology update Room Kairo page 12				
16:30 - 17:00	Coffee break with poster session & exhibition					
17:00 - 18:00	Closing Session Multisectoral response to a multisectoral challenge Room Shanghai page 12					
18:00 - 19:00	Farewell reception in the exhibition hall					

Day 2
7 Mar.

Pre-conference

Room Kairo

09:00 - 11:00 **BEAM Alliance General Assembly**
for BEAM members only



Room Shanghai

09:30 - 11:00 Pre-conference workshop
Milestone-driven R&D – opportunities and challenges
jointly organized by



Introduction

Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria

Integrating TPPs and TCPs in discovery strategies

Malcolm Page, Antibiotic Research

Data-driven decision making in antibiotics preclinical research

Kenneth Bradley, F. Hoffmann-La Roche Ltd

Discussion

Day 1
6 Mar.

Opening Session

Room Shanghai

11:30 - 13:00 **2024, a decisive year - update on the AMR environment**

Marc Gitzinger, BioVersys AG & BEAM Alliance

Judith Moore, World Economic Forum

Alexandra Cameron, World Health Organization

Wolfgang Philipp, European Commission DG HERA

Jonathan Pearce, Antibiotic Research UK

Zoe Molyneux, Wellcome Trust

Alan Donnelly, G20 Health & Development Partnership

Room Shanghai

13:00 - 13:15 **Announcement of the new CARB-X funding rounds**

Themes and timelines of the
new CARB-X funding rounds

hosted by



Erin Duffy, CARB-X

Parallel Sessions

Room Shanghai

14:00 - 15:30 Taking actions on pull incentives

Kevin Outterson, Boston University & CARB-X

Pierre Dubois, Toulouse School of Economics

Damiët Onderstal, European Commission DG HERA

Pietro Erba, European Commission DG SANTE

further speakers to be confirmed

Room Delhi

14:00 - 15:30 Preclinical models to optimize translation to human

Martin Everett, Aurobac Therapeutics

Ian Morrissey, Antimicrobial Focus Ltd

Caterina Bissanz, F. Hoffmann-La Roche Ltd

Coen van Hasselt, Leiden University

Christopher Darlow, Liverpool University

Markus Zeitlinger, Medical University of Vienna

Nicolas Tesse, Septeos

Day 1
6 Mar.

Room Kairo

14:00 - 15:30 Vaccines to keep AMR at bay

Marianne Holm, Novo Nordisk Foundation

Ed Buurman, CARB-X

Ramanan Laxminarayan, One Health Trust

Patricia Martin, LimmaTech Biologics AG

Laura Plant, International Vaccine Institute

Mateusz Hasso-Agopsowicz, World Health Organization

Parallel Sessions

Room Shanghai

16:00 - 17:30 **Meaningful clinical trials: combining regulatory and clinical differentiation needs**

Glenn Dale, BioVersys AG

Radu Botgros, European Medicines Agency

Mark Jones, Basilea Pharmaceutica International Ltd

Ulrich Granzer, Granzer Regulatory Services GmbH

David Paterson, National University of Singapore

Room Delhi

16:00 - 17:30 **Novel disruptive approaches to fight AMR**

hosted by  **NCCR AntiResist**

Christoph Dehio, NCCR AntiResist

Maximiliano G. Gutierrez, Francis Crick Institute

Lucas Boeck, University of Basel

Claudia Zampaloni, F. Hoffmann-La Roche Ltd

Day 1
6 Mar.

Room Kairo

16:00 - 17:30 **How can AI foster prevention and smart use of antibiotics in a One Health world?**

supported by  **GLOBAL AMR R&D HUB**

Lothar Wieler, Hasso Plattner Institute

Ralf Sudbrak, Global AMR R&D Hub

Ramanan Laxminarayan, One Health Trust

Lara Urban, Helmholtz Munich

Thomas van Boeckel, ETH Zurich

Muna Abu-Sin, Robert Koch Institute

18:00–19:30 **Start-up pitch**

hosted by 

Prize sponsor  VOSSIUS

Douglas Häggström, INCATE

Running order of pitching companies:

TabriX, presented by Marc Creus

BrlgID Biologics, presented by Soumya Palliyil

BamA Inhibitor, presented by Till Schäberle

Microplate Dx, presented by Stuart Hannah

Omnicin Therapeutics, presented by Auke van Heel

Obulytix, presented by Yves Briers

Tolka AI Therapeutics, presented by Johan Wikstrom

Generare, presented by Guillaume Vandenesch

Theralia AB, presented by Baris Ata Borsa

Puray, presented by Martin Duffner

Smartbax, presented by Robert Macsics

Day 1
6 Mar.

Plenary Session

Room Shanghai

08:30 - 09:30 A phage cocktail for breakfast?

Valeria Gigante, World Health Organization

Mercedes Gonzalez Moreno, INCATE

Alexander Belcredi, BioNTech R&D (Austria) GmbH

Thilo Köhler, University of Geneva

Shawna McCallin, Balgrist University Hospital Zurich

Parallel Sessions

Room Shanghai

10:00 - 11:30 Making the case for investing in AMR R&D

Marie Petit, Villiger Valuation

Carly Levine, AMR Action Fund

Marc Lemonnier, Antabio

further speakers to be confirmed

Day 2
7 Mar.

Room Delhi

10:00 - 11:30 Tuberculosis: new tools against an old enemy

Suvanand Sahu, STOP TB Partnership

Claire Jordan Brooks, University Carlos III Madrid

Hoon Sang Lee, RIGHT Foundation

Fuad Mirzayev, World Health Organization

Nelly Badalato, Genoscreen

Room Kairo

10:00 - 11:30 New tricks to combat fungal infections

Mark Jones, Basilea Pharmaceutica International Ltd

Dionysios Neofytos, University Hospitals Geneva

Nina Khanna, University Hospital Basel

Mai Hoang, Dynamic42 GmbH

Mark Jones, Basilea Pharmaceutica International Ltd

Parallel Sessions

Room Shanghai

13:00 - 14:30 Push funding: a lifeline for R&D

Remko van Leeuwen, SurvivX

Dennis M. Dixon, NIAID, US National Institutes of Health

Clive Mason, LifeArc

Laura Marin, Joint Programming Initiative on Antimicrobial Resistance

Alessandra Martini, European Commission DG RTD

Jean-Baptiste Perrin, European Commission DG HERA

Damiano de Felice, CARB-X

Room Delhi

13:00 - 14:30 Fast, reliable and cost-effective diagnostics

hosted by



Jens Hellwage, InfectoGnostics Research Campus Jena

Milovan Stankov-Pugès, NG Biotech

Adrian Egli, University of Zurich

Rafael Cantón, Ramon y Cajal Hospital

Eva Rennen, Nostics

Surbhi Malhotra, University of Antwerp

Betsy Wonderly Trainor, CARB-X

Day 2
7 Mar.

Room Kairo

13:00 - 14:30 The true value of antimicrobial products

hosted by



Deepali Patel, AMR Action Fund

Jennifer Quinn, Debiopharm International SA

Michele Cecchini, OECD

Sophie Cooper, UK National Institute for Health and Care Excellence (NICE)

Pierre Dubois, Toulouse School of Economics

Rachel Freeman, IQVIA

Maria Larsson Ortino, Legal & General Investment Management

Parallel Sessions

Room Shanghai

15:00 - 16:30 **Greatest reach to the greatest need**

Jennifer Cohn, GARDP

Alexandra Cameron, World Health Organization

Mirfin Mpundu, ReAct Africa

Michael Anderson, MedAccess

Yann Ferrisse, GARDP

Brenda Waning, STOP TB Partnership

Olivier Menzel, Swiss Agency for Development and Co-Operation

Room Dehli

15:00 - 16:30 **Leveraging the power of diagnostics in clinical practice**

Till Bachmann, University of Edinburgh

Gail Hayward, University of Oxford

Maarten Postma, University of Groningen

Magda Rosenmöller, IESE Business School

Gemma Johnson, OLM Diagnostics

Toby Leslie, The Fleming Fund

Day 2
7 Mar.

Room Kairo

15:00 - 16:30 **Technology update**

Peter Jackson, Infex Therapeutics Ltd

Susana Tomásio, Collaborative Drug Discovery

John Cadwell, FiberCell Systems Inc.

Hee-Jong Hwang, A&J Science

Matti Jalasvuori, PrecisionPhage Oy

Colm Leonard, Infex Therapeutics Ltd

Closing Session

Room Shanghai

17:00 - 18:00 **Multisectoral response to a multisectoral challenge**

Florence Séjourné, Aurobac Therapeutics

Cary Adams, Union for International Cancer Control

Pratik Bhatnagar, IQVIA

Mark Albrecht, US Department of Health and Human Services

Aanika Dalal, Alliance for Reducing Microbial Resistance (ARMoR)

Exhibitors


Booth	Exhibitor	
# 1	Collaborative Drug Discovery Inc.	
# 2	Centre for Process Innovation Ltd	
# 3	Cerdak (Pty) Ltd	
# 4	Infex Therapeutics Ltd	
# 5	BioVersys AG	
# 6	Leibniz Health Technologies	
# 7	Infectognostics Research Campus Jena e.V.	
# 8	IMI AMR Accelerator	
# 9	German Center for Infection Research e.V.	
# 10	INCATE	
# 11	WuXi AppTec	
# 12	Aurobac Therapeutics SAS	
# 13	bioMérieux S.A.	
# 14	Resistell AG	
# 15	Basilea Pharmaceutica International Ltd	
# 16	Global Antibiotic Research & Development Partnership	
# 17	Asymchem Inc.	
# 18	PrecisionPhage Ltd	
# 19	Selvita S.A.	
# 20	FiberCell Systems Inc. / Bio-Connect	
# 21	Rime Bioinformatics SAS	
# 22	Symcel AB	
# 23	Epithelix Sàrl	

Floor Map

Venue:

Congress Center Basel
Hall 4
Messeplatz 21
4058 Basel, Switzerland





Riehenstrasse / Messeplatz

- | | |
|--|--|
| ■ Program Rooms | ■ Meeting Room Innovate UK |
| ■ Exhibitor Booths | ■ Partnering Area |
| ■ Catering | □ Poster Exhibition |

Poster Exhibition

No.	Title	Corresponding Author
1	Bacterial Impedance Cytometry (BIC) - Gaining insights into bacterial responses to antimicrobials	Lucy Bock , UK Health Security Agency
2	Microfluidic platform to visualize and quantify bacterial response to dynamic drug treatments	Friederike Born , ETH Zurich
3	An anti-virulence strategy to treat Salmonella infections: Development of lead compounds targeting the transcriptional regulator HlID	Hakim Boudrioua , University Hospital Tübingen
4	A VersaTile-driven, AI-augmented platform for the development of customized phage lysin-based antibiotics	Yves Briers , Ghent University
5	Phage development for clinical applications	Karine Charton , Phaxiam Therapeutics S.A.
6	Mechanism of action studies using systematic analysis platform	Jan-Martin Daniel , University of Bonn
7	HoloMoA: Combination of time-lapse quantitative phase imaging with deep learning for rapidly detecting the Mechanism of Action of an antimicrobial and its potential novelty	Sophie Dixneuf , BIOASTER
8	Decoding polymicrobial interactions in catheter-associated urinary tract infections	Ashim Dubey , Ecole Polytechnique fédérale de Lausanne
9	Faecal Microbiota Transplantation, a novel treatment to tackle Antimicrobial Resistance in Chronic Liver Disease – induces phage network remodeling and enteric pathogen reduction, enhances intestinal barrier function and immunometabolism, altering mucosal IL-17 immunity	Lindsey Edwards , King's College London
10	Novel AI platform for antimicrobial drug discovery	Yojana Gadiya , Fraunhofer ITMP ScreeningPort
11	DCB001: a new precision antibiotic candidate against MRSA	Juan Garcia-Sanchez , Université Côte d'Azur
12	Metabolism-guided optimization of next-generation benzothiazinones towards highly potent antituberculosis agents	Sina Gerbach , Leibniz Institute for Natural Product Research and Infection Biology
13	Inhibition and eradication of Pseudomonas aeruginosa biofilms by secondary metabolites of Nocardia opsis lucentensis EMB25	Nikky Goel , IIT DELHI
14	Dual mode of Action Broad-spectrum Bacterial Gyrase Inhibition by the Peptide Antibiotic Albicidin	Frank Gombert , Selmod GmbH
15	Disperazol: treating Pseudomonas aeruginosa catheter associated urinary tract biofilm infections	Michael Graz , Biophys Ltd
16	Invasive aspergillosis-on-chip: A quantitative treatment study of human Aspergillus fumigatus infection	Mai Hoang , Dynamic42 GmbH

No.	Title	Corresponding Author
17	SimCells: genome-free bacterial cells as vaccines against <i>Pseudomonas aeruginosa</i> infections	Jane Hsu, Oxford SimCell Ltd
18	Modeling of intravenous caspofungin administration using an intestine-on-chip reveals altered <i>Candida albicans</i> microcolonies and pathogenicity	Tim Kaden, Dynamic42 GmbH
19	Utilising optical electrophysiology for rapid antimicrobial susceptibility testing to enhance bloodstream infections and sepsis management	Magdalena Karlikowska, Cytecom Ltd.
20	The COMBINE Preclinical Bacterial Strain Repository - A new resource for preclinical lung infection models to assess antibiotic efficacy	Bernhard Kerscher, Paul-Ehrlich-Institute
21	New rapid detection of beta-lactamase producing bacteria using fluorogenic probes	Anne Khoschnud, Molsid S.A.S.
22	Intracellular growth and persistence of <i>Pseudomonas aeruginosa</i> in a lung tissue model	Luisa Lauer, University of Basel
23	Paride - a new <i>Pseudomonas aeruginosa</i> phage	Enea Maffei, ETH Zurich
24	Identification of new antimicrobial resistance genes in <i>E. coli</i> through network diffusion	Anis Mansouri, University of Bologna
25	Empowering Antibiotics in the AMR Landscape: Insights from Dendrimer Conjugation in ALI systems	Laura Martinenghi, Copenhagen University
26	The DSMZ bacteriophage collection and its relevance for fighting antimicrobial resistance	Filipa Martins, DSMZ-German Collection of Microorganisms and Cell Cultures GmbH
27	An MD simulation-enhanced machine learning virtual screening for permeability and accumulation of antimicrobials	Stefan Milenkovic, University of Cagliari, Physics Department
28	Facilitating Phage Applications in Africa and Asia	Tobi Nagel, Phages for Global Health
29	Dimercaptosuccinic acid in combination with carbapenems against strains of <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> producing metallo-β-lactamase in a murine peritonitis model	Patrice Nordmann, Université de Fribourg
30	Novel antibiotic peptides in the fight against AMR	Marit Otterlei, Norwegian University Of Science and Technology
31	Proteomics: Revolution in bacteria identification and AMR detection in one	Armand Paauw, Netherlands Organization for Applied Scientific Research TNO
32	Human bladder microtissue model to study chronic and recurrent UTIs	Gauri Paduthol, Ecole Polytechnique federale de Lausanne
33	Human monoclonal antibodies targeting novel, fungal cell wall proteins offer superior therapeutic efficacy in a preclinical model of infection	Soumya Palliyil, University of Aberdeen
34	Chemistry Center for Combating Antibiotic Resistant Bacteria (CC4CARB)	Elliott Pauli, RTI International

No.	Title	Corresponding Author
35	How GARDP's REVIVE platform is providing open-access tools and resources for the antimicrobial R&D community	Astrid Pentz-Murr , GARDP
36	The human microbiome as source and target for new antibacterial compounds	Andreas Peschel , University of Tübingen
37	The Swiss Round Table on Antibiotics fosters the development and availability of antibiotics	Barbara Polek , Round Table on Antibiotics
38	Use of Sub-Cellular Fluctuation Imaging (SCFI) for real-time monitoring of antibiotic resistance in <i>N. gonorrhoeae</i>	James Preece , FluoretiQ Ltd
39	VERI-5.: a compact hardware and single use cartridge system for rapid detection of Urinary Tract Infections	James Preece , FluoretiQ Ltd
40	Self-adjuvant nanovaccination as novel tool to combat bacterial infections	Oliver Reimann , Belyntic GmbH
41	Highly-neutralizing anti-PcrV antibodies as clinical candidates against <i>Pseudomonas aeruginosa</i>	Jan Rybníček , Center for Molecular Medicine Cologne
42	Turning enzymes into efficient enzymiotics	Izabela Sabala , Mossakowski Medical Research Institute PAS
43	Microbialbiosensor for industrial online analysis	Tobias Schröter , FluiDect GmbH
44	Development of a Synthetic Human Urine formulation for the study of uropathogenic <i>E. coli</i> (UPEC) physiology and the discovery of antibiotics	Benjamin Sellner , University of Basel
45	Retrospective analysis of cefiderocol for treating severe drug-resistant gram negative bacterial infections	Leeanne Stewart , Belfast Health And Social Care Trust
46	Exploring Challenges in Vaccine Development for Emerging Pathogens: A Study of Regulatory Interactions between Developers and Regulators	Igor Stojkov , Paul-Ehrlich-Institute
47	New Generation Antimicrobials Developed Using Efflux Resistance Breaker (ERB) Technology	Mark Sutton , UK Health Security Agency
48	An in vivo-like lung infection model for pharmacokinetics and –dynamics studies	Leoni Swart , University of Basel
49	MtpB inhibitors increase the efficacy of antibiotics reducing intracellular burden for <i>Mycobacterium tuberculosis</i> and nontuberculous <i>Mycobacterium avium</i>	Lydia Tabernero , University of Manchester
50	Search for the new generation of the antifungal drugs based on the polyene antibiotics	Anna Tevyashova , Constructor University
51	Human urothelial microtissue model for in vitro studies of urinary tract infection and its treatment	Lisette van Os , University of Basel

No.	Title	Corresponding Author
52	New bioluminescent preclinical infection mouse models using recently isolated strain of multi drug resistant KAPE bacteria	Marc Vandamme , Voxcan
53	Next Generation Assay Optimisation for Drug Screening Using design of experiments and automation for antibiotic adjuvant discovery	Adam Winnifrith , University of Oxford
54	Acceleration of Hit-to-Lead Drug Development by Nanoliter-scale Screening of Mutasynthetic BamA Inhibitor Library	Zerlina Wuisan , University of Giessen
55	BTZ-043 shows good safety and strong bactericidal activity in a seamless phase 1b/2a study in patients with pulmonary TB	Julia Dreisbach , University Hospital Munich
56	Granulytics: Antimicrobial protein-lipid complexes derived from the human immune peptides to tackle Antimicrobial resistance	Owais Hameed , Université de Fribourg
57	High-throughput sequencing technologies for genome methylation analysis and possible epigenetic intervention strategies in the model bacterium <i>Helicobacter pylori</i>	Christine Josenhans , Ludwig Maximilian University Munich
58	Novel thiopeptides to target intractable bacterial infections	Clovis Shyaka , A&J Science
59	From Stress to Adaptive Success: A systematic investigation of physiological adaptation of <i>Escherichia coli</i> facing harsh environments	Alexandra Evelynne Huber , University of Basel
60	Combining growth inhibition assays and metabolic profiling to accelerate discovery of antibiotics with unconventional modes of action	Sebastián Sosa-Carrillo , University of Basel

The pre-scheduled one-to-one meetings take place as follows:

Day 1, 6 March: 10:00 - 19:00

Day 2, 7 March: 08:30 - 18:00

The length of each meeting slot is 30 minutes. Please check your individual meeting schedule for times and locations of your confirmed meetings.

Meeting locations: Exhibition Hall

Need help? Please see the Partnering Help Desk at the registration.

Thank you to our sponsors, exhibitors and partners

Local Host



Platinum Sponsors



Gold Sponsors



Silver Sponsors



Bronze Sponsors



Supporting Partners



Room for your notes

Room for your notes



The 9th AMR Conference

Novel Antimicrobials & AMR Diagnostics

will return to the Congress
Center Basel in **March 2025**

Stay tuned for updates

amr-conference.com
#AMRconference



Organization: bamconn GmbH | Erholungsweg 51 | 13509 Berlin
Boris Mannhardt | info@bamconn.eu | Tel. +49 (0)176 101 439 86

bamconn